Combination Oncology - Pt.2 How potential launch scenarios influence pricing : IC Fireside Chats - Episode 13
The strategy behind combination therapy launch sequencing isn’t just about timing — it can dramatically reshape your pricing outcomes. In this second episode on oncology combinations, we dig into launch scenarios, evidence generation timelines, and why some deals end up hurting the value of later products. Adam and Omar unpack the tension between short-term wins and long-term market shaping.
Key themes:
How pricing is influenced by which product launches first
Real-world missteps and their consequences
The fine line between data readiness and market readiness
Disclaimer: This presentation is for educational and informational purposes only, and is not intended as legal or policy advice. This presentation is based on non-confidential intelligence. Views expressed by the speakers are personal opinions and should not be attributed to anyone else. No part of this presentation may be reproduced for commercial purposes without the express permission of Verpora.
Never miss an episode
Receive a single email each week with a direct link to the latest IC Fireside Chat— no spam, just the latest episode, straight to your inbox.
Watch Next
